Table 2 The clinical characteristics of the enrolled patients at baseline
Variables | Whole | CVs | Non-CVs | Pa |
|---|---|---|---|---|
(n = 386) | (n = 92) | (n = 294) | ||
Characteristics | ||||
Age (years) | 72.7 ± 5.4 | 72.9 ±5.2 | 72.8 ± 5.5 | 0.568 |
Male | 269/386 (69.7) | 65/92 (70.6) | 204/294 (69.4) | 0.818 |
BMI (kg/m2) | 23.6 ± 2.1 | 24.3 ± 2.3 | 23.4 ± 2.2 | 0.001 |
Cardiovascular disease risk factors | ||||
Hypertension | 270/386 (69.9) | 64/92 (69.6) | 206/294 (70.1) | 0.927 |
Dyslipidemia | 246/386 (90.2) | 83/92 (90.2) | 265/294 (90.1) | 0.982 |
Smoking, current or former | 246/386 (63.7) | 59/92 (64.1) | 187/294 (63.6) | 0.927 |
Family history | 82/386 (21.2) | 21/92 (22.8) | 61/294 (20.7) | 0.671 |
Medications | ||||
Calcium-channel blocker | 165/386 (42.7) | 48/92 (52.2) | 117/294 (39.8) | 0.036 |
ACEI | 212/386 (54.9) | 56/92 (60.9) | 156/294 (53.1) | 0.189 |
ARB | 172/386 (14.8) | 40/92 (43.5) | 132/294 (44.9) | 0.943 |
β-blocker | 114/386 (44.5) | 27/92 (29.3) | 87/294 (29.6) | 0.964 |
Aspirin | 347/386 (89.9) | 84/92 (91.3) | 263/294 (89.5) | 0.608 |
Insulin | 27/386 (7.0) | 12/92 (13.0) | 15/294 (5.1) | 0.009 |
Sulfonylurea | 147/386 (40.0) | 74/92 (80.0) | 73/294 (25.0) | 0.001 |
Metformin | 38/386 (10.0) | 9/92 (9.7) | 29/294 (10.0) | 0.999 |
α-Glucosidase inhibitor | 127/386 (33.0) | 54/92 (58.6) | 73/294 (25.0) | 0.001 |
Thiazolidine | 69/386 (18.0) | 49/92 (53.2) | 20/294 (6.8) | 0.001 |
Statin | 224/386 (58.0) | 47/92 (51.1) | 162/294 (55.1) | 0.501 |